Last updated: February 13, 2026
Overview
NDC 25021-0121 is a medication marketed under the brand name Vitrakvi (larotrectinib). It is an oral kinase inhibitor developed by Bayer and acquired by Loxo Oncology, administered for treating adult and pediatric patients with NTRK gene fusions across various tumor types. Approved by the FDA in November 2019, Vitrakvi represents a targeted therapy with a broad oncology application but limited patient population.
Market Size and Adoption Trends
Patient Population
Vitrakvi's approval is tumor-agnostic, covering any solid tumor with NTRK gene fusions. Estimated patient numbers are limited initially:
- Estimated annual U.S. patient volume: 1,000 - 2,000 based on prevalence of NTRK fusions in solid tumors.
- Global market: approximately 3,000 - 5,000 patients annually, considering global cancer incidence and fusion prevalence.
Market Penetration
- Initial adoption driven by oncologists' familiarity with genetic testing.
- Diagnostic testing for NTRK fusions remains a bottleneck; increased testing will expand the addressable market.
- Oncology repositioning and healthcare provider education will impact growth.
Market Dynamics
- Competition from other TRK inhibitors, such as Entrectinib (Rozlytrek) from Roche and Repotrectinib (still under clinical evaluation).
- Rising use of NGS-based testing, expanding eligible patient diagnosis.
Pricing and Reimbursement Environment
Current Pricing in U.S.
- List Price: approximately $16,000 per month (retail prescription).
- Annual cost: around $192,000 when used continuously.
Reimbursement Rates
- Insurance coverage is generally robust due to FDA approval and marketed status.
- Patient assistance programs and negotiated discounts influence net prices.
Price Trends
- List prices show stability with minimal discounting, factoring in high R&D costs and rare disease status.
- Negotiated prices may fall 10-30% in practice, particularly in value-based arrangements.
Price Trajectory Projections (Next 5 Years)
| Year |
Expected Price Range (per month) |
Comments |
| 2023 |
$15,500 - $16,000 |
Baseline, market stabilization |
| 2024 |
$15,000 - $16,000 |
Slight discounts for managed care |
| 2025 |
$14,500 - $15,500 |
Competition from newer agents, market expansion |
| 2026 |
$14,000 - $15,000 |
Potential price reductions with increased testing |
| 2027 |
$13,500 - $14,500 |
Entry of biosimilar or alternative therapies |
Factors Affecting Pricing
- Expansion of diagnostic testing reduces upfront costs and accelerates market share.
- Approval of competing therapies impacts pricing pressure.
- Changes in healthcare policy and reimbursement strategies.
Competitive Landscape and Impact on Price
Key Competitors
- Entrectinib (Rozlytrek): Approved for NTRK fusion-positive cancers; list price comparable, around $17,000/month.
- Other emerging agents: Under clinical trials, with potential for later entry and price competition.
Market Share Considerations
- Expected to grow steadily as testing improves.
- Price competition may erode margins among providers.
Regulatory and Policy Factors
- Extended indications and label expansions may increase patient access.
- Policy shifts towards value-based care may pressure prices downward.
- Payer negotiations tend to influence net prices more than list prices.
Summary of Key Data Points
| Aspect |
Data |
| Approved indications |
NTRK fusion-positive solid tumors |
| Initial annual U.S. sales |
Estimated $200 - $300 million based on patient volume |
| List price (2023) |
~$16,000/month |
| Competitive threats |
Rozlytrek, clinical-stage TRK inhibitors |
| Reimbursement environment |
Favorable, with usage-based discounts |
Key Takeaways
- Vitrakvi operates in a niche but expanding market for targeted oncology
- Listing prices remain high, but discounts and negotiations will likely reduce net prices over time
- Market growth depends heavily on diagnostic testing expansion and recognition of efficacy across tumor types
- Competition from other TRK inhibitors and potential biosimilars will influence pricing strategies
- Regulatory developments and policy shifts could impact future market size and pricing
FAQs
1. How does Vitrakvi’s pricing compare to similar therapies?
Vitrakvi’s list price approximates other TRK inhibitors like Entrectinib, with slight variations depending on manufacturer pricing strategies and negotiated discounts.
2. What will drive price reductions for NDC 25021-0121?
Wider adoption of comprehensive genetic testing and entry of biosimilar or generic options will pressure prices downward.
3. How significant is the role of diagnostics in market expansion?
Critical. Increasing routine NTRK fusion testing in cancer diagnosis will expand eligible patient numbers, impacting sales volume more than price.
4. Are there any planned label expansions that could influence pricing?
Future label expansions related to additional tumor types could increase market size but may not immediately alter pricing unless linked with competitive pressures.
5. What is the potential impact of biosimilar entry?
Biosimilars for kinase inhibitors typically take several years to develop. Their introduction would likely reduce prices significantly if they prove equivalent in efficacy and safety.
Citations
- U.S. Food and Drug Administration. Vitrakvi (larotrectinib) Approvals. 2019.
- IQVIA. Healthcare Data and Market Reports. 2023.
- EvaluatePharma. World Preview 2023, Outlook to 2028.
- National Cancer Institute. NTRK Fusion-Positive Cancers. 2022.
- Securities and Exchange Commission filings, Bayer and Loxo Oncology financial disclosures.
